Roy Barry Tishler, Ph.D., M.D.
Co-Author
This page shows the publications co-authored by Roy Tishler and Robert Haddad.
Connection Strength
7.655
-
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 2009 Oct 01; 115(19):4514-23.
Score: 0.419
-
Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. J Clin Oncol. 2008 May 20; 26(15_suppl):6001.
Score: 0.381
-
Multidisciplinary approach to cancer treatment: focus on head and neck cancer. Dent Clin North Am. 2008 Jan; 52(1):1-17, vii.
Score: 0.371
-
Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1036-44.
Score: 0.331
-
Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol. 2006 Apr; 29(2):153-7.
Score: 0.328
-
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 02 01; 28(3):468-478.
Score: 0.241
-
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570.
Score: 0.224
-
Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. Ann Oncol. 2012 Sep; 23(9):2391-2398.
Score: 0.212
-
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019 03 01; 30(3):471-477.
Score: 0.201
-
IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head Neck. 2019 04; 41(4):959-966.
Score: 0.199
-
Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncol. 2017 10; 73:160-165.
Score: 0.181
-
Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. Front Oncol. 2017; 7:191.
Score: 0.181
-
Highlights in Head and Neck Cancer. JAMA Oncol. 2017 04 01; 3(4):441-442.
Score: 0.176
-
Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial. Oncologist. 2016 12; 21(12):1522-1529.
Score: 0.168
-
Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. Oral Oncol. 2016 10; 61:19-26.
Score: 0.168
-
Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. Head Neck. 2016 04; 38 Suppl 1:E1618-24.
Score: 0.160
-
Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013; 18(3):294-300.
Score: 0.132
-
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013 Mar; 14(3):257-64.
Score: 0.132
-
Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. Ann Oncol. 2012 Sep; 23(9):2391-2398.
Score: 0.124
-
Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial. Contemp Clin Trials. 2012 Jul; 33(4):700-11.
Score: 0.124
-
Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e215-22.
Score: 0.117
-
Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys. 2011 Aug 01; 80(5):1405-11.
Score: 0.114
-
Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):308-14.
Score: 0.113
-
Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer. 2010 Oct 15; 116(20):4761-8.
Score: 0.112
-
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol. 2010 Feb; 21(2):342-347.
Score: 0.105
-
Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009 Sep 20; 27(27):4448-53.
Score: 0.104
-
Retropharyngeal nodes in hypopharynx cancer on positron emission tomography. J Clin Oncol. 2007 Feb 10; 25(5):599-601.
Score: 0.087
-
Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer. Otolaryngol Head Neck Surg. 2006 Jun; 134(6):916-22.
Score: 0.083
-
Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2006 Jun; 132(6):678-81.
Score: 0.083
-
Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006 May; 132(5):526-31.
Score: 0.083
-
Integrating novel agents into the curative treatment of head and neck cancer. Expert Rev Anticancer Ther. 2006 Feb; 6(2):157-9.
Score: 0.081
-
Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol. 2005 Aug; 28(4):371-8.
Score: 0.078
-
Rate of complete pathological responses (pCR) to docetaxel/cisplatin/5-fluorouracil (TPF) induction chemotherapy in patients with newly diagnosed, locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2005 Jun; 23(16_suppl):5511.
Score: 0.077
-
Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol. 2004 Dec; 31(6):778-85.
Score: 0.075
-
A phase I/II study of docetaxel (D) and concomitant boost radiation (CBR) for patients with squamous cell cancer of the head and neck (SCCHN) following induction chemotherapy (IC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5548.
Score: 0.073
-
Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5600.
Score: 0.073
-
Nonsurgical treatment of laryngeal cancer. N Engl J Med. 2004 Mar 04; 350(10):1049-53; author reply 1049-53.
Score: 0.071
-
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003 Jan 15; 97(2):412-8.
Score: 0.066
-
Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist. 2003; 8(1):35-44.
Score: 0.066
-
Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. Head Neck. 2022 Mar 31.
Score: 0.062
-
Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes. Head Neck. 2022 03; 44(3):722-734.
Score: 0.061
-
Exposed bone in patients with head and neck cancer treated with radiation therapy: An analysis of the Observational Study of Dental Outcomes in Head and Neck Cancer Patients (OraRad). Cancer. 2022 02 01; 128(3):487-496.
Score: 0.060
-
Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncol. 2021 01; 112:105087.
Score: 0.056
-
Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Head Neck. 2020 12; 42(12):3670-3677.
Score: 0.056
-
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):134-144.
Score: 0.056
-
The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist. 2020 07; 25(7):598-608.
Score: 0.054
-
Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncol. 2020 07; 106:104690.
Score: 0.054
-
Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2020 06; 105:104676.
Score: 0.054
-
Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019 10; 28(10):1660-1667.
Score: 0.052
-
A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):132-139.
Score: 0.051
-
Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019; 9:106.
Score: 0.050
-
Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):137-145.
Score: 0.048
-
The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 11; 22(11):1413.
Score: 0.046
-
The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 03; 22(3):343-350.
Score: 0.044
-
Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017; 19(2):129-136.
Score: 0.043
-
Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer. 2016 Dec 01; 122(23):3632-3640.
Score: 0.042
-
Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016 07 12; 115(2):252-60.
Score: 0.042
-
Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. J Immunother Cancer. 2016; 4:32.
Score: 0.042
-
Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. Head Neck. 2016 10; 38(10):1530-8.
Score: 0.041
-
Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2016 06 15; 22(12):2939-49.
Score: 0.040
-
Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Oncol Pract. 2015 Mar; 11(2):151-4.
Score: 0.038
-
Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Clin Oncol. 2014 Oct 20; 32(30_suppl):100.
Score: 0.037
-
Success of endoscopic pharyngoesophageal dilation after head and neck cancer treatment. Laryngoscope. 2013 Dec; 123(12):3066-73.
Score: 0.034
-
Organ preservation for adenoid cystic carcinoma of the larynx. Oncologist. 2013; 18(5):579-83.
Score: 0.033
-
Swallowing function following postchemoradiotherapy neck dissection: review of findings and analysis of contributing factors. Otolaryngol Head Neck Surg. 2011 Sep; 145(3):428-34.
Score: 0.030
-
Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):e813-8.
Score: 0.029
-
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011 Feb; 12(2):153-9.
Score: 0.029
-
Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy. Otolaryngol Head Neck Surg. 2010 Sep; 143(3):367-74.
Score: 0.028
-
Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis. Laryngoscope. 2010 Feb; 120(2):261-6.
Score: 0.027
-
Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009 Nov 01; 75(3):725-33.
Score: 0.025
-
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009 May; 20(5):921-7.
Score: 0.025
-
Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):1110-8.
Score: 0.024
-
Sequential therapy for locally advanced larynx and hypopharynx cancer: Subgroup analysis from the TAX 324 Study. J Clin Oncol. 2008 May 20; 26(15_suppl):6031.
Score: 0.024
-
Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). J Clin Oncol. 2008 May 20; 26(15_suppl):6007.
Score: 0.024
-
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25; 357(17):1705-15.
Score: 0.023
-
Chemoradiation-induced cell loss in human submandibular glands. Laryngoscope. 2005 Jun; 115(6):958-64.
Score: 0.019
-
Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck cancer. Laryngoscope. 2004 Nov; 114(11):1924-31.
Score: 0.019
-
Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004 Oct; 26(10):890-6.
Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.